Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294710 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 976
- Enrollment target
NCT00294710 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 976 participants.
The verdict
NCT00294710, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 976 participants
- Enrollment target
Study Summary
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension
Interventions
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 976 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294710
The ClinicalTrials.gov registry entry for NCT00294710 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 976 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aliskiren is the first listed.
NCT00294710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294710 about?
NCT00294710 is a clinical study titled "A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine". This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension
What is the current status of trial NCT00294710?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 976 participants. The study started on 2005-03. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00294710?
The interventions under investigation include: Aliskiren (DRUG).
Who is sponsoring clinical trial NCT00294710?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.